INNOVIVA, INC. (INVA) Free cash flow
- Free cash flow · 12 months (USD): Value $189.44M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value 43.06%; Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $189.44M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $191.49M − $2.05M ≈ $189.44M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | 43.06% | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. $189.44M ÷ $440.00M × 100 ≈ 43.06% |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $191.49M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | (m) | Operating cash flow / net income. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | 191.49M USD | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations |
| Capital spending | 2.05M USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | 189.44M USD | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 440.00M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | (m) | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $189.44M | (m) | $191.49M | $2.05M | (m) | $440.00M | (m) | (m) | (m) | (m) | 43.06% | (m) |
| 2026-03-31 | $181.97M | (m) | $183.59M | $1.62M | (m) | $420.69M | (m) | (m) | (m) | (m) | 43.26% | (m) |
| 2025-12-31 | $195.80M | (m) | $196.93M | $1.13M | (m) | $411.33M | (m) | (m) | (m) | (m) | 47.60% | (m) |
| 2025-09-30 | $200.53M | (m) | $201.66M | $1.12M | (m) | $388.52M | (m) | (m) | (m) | (m) | 51.61% | (m) |
| 2025-06-30 | (m) | (m) | $200.62M | (m) | (m) | $370.23M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | (m) | $200.26M | (m) | (m) | $369.84M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $188.42M | (m) | $188.69M | $270.00K | (m) | $358.71M | (m) | (m) | (m) | (m) | 52.53% | (m) |
| 2024-09-30 | $162.29M | (m) | $162.71M | $421.00K | (m) | $352.75M | (m) | (m) | (m) | (m) | 46.01% | (m) |
| 2024-06-30 | $157.59M | (m) | $157.96M | $378.00K | (m) | $330.50M | (m) | (m) | (m) | (m) | 47.68% | (m) |
| 2024-03-31 | $152.05M | (m) | $152.43M | $378.00K | (m) | $311.59M | (m) | (m) | (m) | (m) | 48.80% | (m) |
| 2023-12-31 | $140.65M | (m) | $141.06M | $411.00K | (m) | $310.46M | (m) | (m) | (m) | (m) | 45.30% | (m) |
| 2023-09-30 | $116.41M | (m) | $116.71M | $294.00K | (m) | $290.43M | (m) | (m) | (m) | (m) | 40.08% | (m) |
| 2023-06-30 | $88.38M | (m) | $88.45M | $78.00K | (m) | $290.42M | (m) | (m) | (m) | (m) | 30.43% | (m) |
| 2023-03-31 | $129.22M | (m) | $129.31M | $91.00K | (m) | $317.65M | (m) | (m) | (m) | (m) | 40.68% | (m) |
| 2022-12-31 | $201.66M | (m) | $201.73M | $67.00K | (m) | $331.34M | (m) | (m) | (m) | (m) | 60.86% | (m) |
| 2022-09-30 | $291.18M | (m) | $291.21M | $33.00K | (m) | $373.22M | (m) | (m) | (m) | (m) | 78.02% | (m) |
| 2022-06-30 | $372.21M | (m) | $372.23M | $22.00K | (m) | $403.82M | (m) | (m) | (m) | (m) | 92.17% | (m) |
| 2022-03-31 | $377.80M | (m) | $377.81M | $9.00K | (m) | $396.41M | (m) | (m) | (m) | (m) | 95.31% | (m) |
| 2021-12-31 | $363.81M | (m) | $363.81M | $0.00 | (m) | $391.87M | (m) | (m) | (m) | (m) | 92.84% | (m) |
| 2021-09-30 | $350.71M | (m) | $350.71M | $0.00 | (m) | $374.66M | (m) | (m) | (m) | (m) | 93.61% | (m) |
| 2021-06-30 | $328.56M | (m) | $328.56M | $0.00 | (m) | $365.49M | (m) | (m) | (m) | (m) | 89.89% | (m) |
| 2021-03-31 | $323.74M | (m) | $323.74M | $0.00 | (m) | $343.63M | (m) | (m) | (m) | (m) | 94.21% | (m) |
| 2020-12-31 | $313.10M | (m) | $313.11M | $13.00K | (m) | $336.79M | (m) | (m) | (m) | (m) | 92.96% | (m) |
| 2020-09-30 | $294.71M | (m) | $294.74M | $25.00K | (m) | $322.29M | (m) | (m) | (m) | (m) | 91.44% | (m) |
| 2020-06-30 | $277.56M | (m) | $277.58M | $25.00K | (m) | $299.35M | (m) | (m) | (m) | (m) | 92.72% | (m) |
| 2020-03-31 | $254.26M | (m) | $254.28M | $25.00K | (m) | $284.51M | (m) | (m) | (m) | (m) | 89.37% | (m) |
| 2019-12-31 | $257.45M | (m) | $257.46M | $12.00K | (m) | $261.02M | (m) | (m) | (m) | (m) | 98.63% | (m) |
| 2019-09-30 | (m) | (m) | $252.33M | (m) | (m) | $264.90M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | $255.04M | (m) | (m) | $260.83M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | $250.27M | (m) | (m) | $263.81M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $223.53M | (m) | $223.53M | $0.00 | (m) | $261.00M | (m) | (m) | (m) | (m) | 85.64% | (m) |
| 2018-09-30 | (m) | (m) | $209.61M | (m) | (m) | $250.67M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | $192.99M | (m) | (m) | $237.63M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | $163.90M | (m) | (m) | $229.10M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $141.75M | (m) | $141.75M | $0.00 | (m) | $217.22M | (m) | (m) | (m) | (m) | 65.26% | (m) |
| 2017-09-30 | $114.95M | (m) | $114.98M | $28.00K | (m) | $191.31M | (m) | (m) | (m) | (m) | 60.08% | (m) |
| 2017-06-30 | $91.40M | (m) | $91.67M | $270.00K | (m) | $175.97M | (m) | (m) | (m) | (m) | 51.94% | (m) |
| 2017-03-31 | (m) | (m) | $81.50M | (m) | (m) | $149.88M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $60.71M | (m) | $60.98M | $278.00K | (m) | $133.57M | (m) | (m) | (m) | (m) | 45.45% | (m) |
| 2016-09-30 | $46.56M | (m) | $46.81M | $251.00K | (m) | $112.79M | (m) | (m) | (m) | (m) | 41.28% | (m) |
| 2016-06-30 | $29.27M | (m) | $29.28M | $9.00K | (m) | $93.05M | (m) | (m) | (m) | (m) | 31.46% | (m) |
| 2016-03-31 | $19.00M | (m) | $19.00M | $1.00K | (m) | $71.23M | (m) | (m) | (m) | (m) | 26.67% | (m) |
| 2015-12-31 | $10.12M | (m) | $10.13M | $7.00K | (m) | $53.95M | (m) | (m) | (m) | (m) | 18.77% | (m) |
| 2015-09-30 | $-1.53M | (m) | $-1.40M | $139.00K | (m) | $38.39M | (m) | (m) | (m) | (m) | -4.00% | (m) |
| 2015-06-30 | $-25.26M | (m) | $-25.12M | $139.00K | (m) | $25.83M | (m) | (m) | (m) | (m) | -97.80% | (m) |
| 2015-03-31 | $-80.78M | (m) | $-81.70M | $-925.00K | (m) | $16.11M | (m) | (m) | (m) | (m) | -501.44% | (m) |
| 2014-12-31 | $-131.41M | (m) | $-130.72M | $689.00K | (m) | $8.43M | (m) | (m) | (m) | (m) | -1558.31% | (m) |
| 2014-09-30 | $-167.71M | (m) | $-166.09M | $1.62M | (m) | $2.85M | (m) | (m) | (m) | (m) | -5880.43% | (m) |
| 2014-06-30 | $-188.19M | (m) | $-186.33M | $1.86M | (m) | $2.27M | (m) | (m) | (m) | (m) | -8297.44% | (m) |
| 2014-03-31 | $-152.22M | (m) | $-148.61M | $3.61M | (m) | $3.58M | (m) | (m) | (m) | (m) | -4253.20% | (m) |
| 2013-12-31 | $-132.34M | (m) | $-129.60M | $2.73M | (m) | $4.76M | (m) | (m) | (m) | (m) | -2781.34% | (m) |
| 2013-09-30 | $-116.25M | (m) | $-114.32M | $1.93M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | $-102.83M | (m) | $-100.58M | $2.26M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | $-120.48M | (m) | $-118.26M | $2.23M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $-130.54M | (m) | $-127.95M | $2.59M | (m) | $135.76M | (m) | (m) | (m) | (m) | -96.16% | (m) |
| 2012-09-30 | $-131.85M | (m) | $-128.62M | $3.23M | (m) | $135.32M | (m) | (m) | (m) | (m) | -97.44% | (m) |
| 2012-06-30 | $-123.01M | (m) | $-120.38M | $2.63M | (m) | $140.32M | (m) | (m) | (m) | (m) | -87.66% | (m) |
| 2012-03-31 | $-107.13M | (m) | $-103.78M | $3.35M | (m) | $145.28M | (m) | (m) | (m) | (m) | -73.74% | (m) |
| 2011-12-31 | $-91.97M | (m) | $-88.34M | $3.63M | (m) | $24.51M | (m) | (m) | (m) | (m) | -375.19% | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $-76.00M | (m) | $-75.14M | $861.00K | (m) | $24.22M | (m) | (m) | (m) | (m) | -313.77% | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $-58.81M | (m) | $-58.06M | $744.00K | (m) | $24.37M | (m) | (m) | (m) | (m) | -241.27% | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |